EUVIMEDEUVIMED entdecken
Crossref

Engineered Bacterial Protoplasts for Spatiotemporally Controlled Tumor Immunotherapy

Yun Zhang, Qian‐Ru Li, Zhu Chen, Xiao Yan, Jin‐Lian He, Bao‐Ting Dong, Xin‐Chen Deng, Jian‐Hua Yan, Si‐Xue Cheng, Xian‐Zheng Zhang

Advanced Functional Materials · 2026-07 · 36 (54)

DOI: 10.1002/adfm.76486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 12.06.2026. Verfasst von Yun Zhang und 9 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine‐expressing bacteria represent a promising candidate for cancer immunotherapy, but their clinical use is limited by systemic toxicity from lipopolysaccharide (LPS) and other endotoxic components. Here, a protoplast‐based delivery platform, designated as FACaC/T@PI, is constructed for tumor immunotherapy. FACaC/T@PI uses protoplast (PI) as the vehicle for tumor cytokine delivery, which is stabilized via glutaraldehyde crosslinking and engineered to overexpress interferon‐γ (IFN‐γ). The PI is coated with a folate‐modified calcium carbonate (CaCO 3 ) layer, which is loaded with the extracellular matrix (ECM) remodeling agent tranilast. In the acidic tumor microenvironment (TME), PI is exposed to serum complement attack after the CaCO 3 protective layer dissolves. The complement can assemble membrane attack complexes on the protoplast membrane, triggering protoplast lysis and the release of IFN‐γ, which induces tumor cell apoptosis and promotes antitumor immune activation. With markedly reduced LPS content and complement‐mediated cargo release, FACaC/T@PI demonstrates efficacy as a low‐toxicity platform for tumor immunotherapy in both breast and pancreatic cancer models. This protoplast‐based delivery vehicle offers valuable perspectives for the development of bacteria‐derived therapeutic platforms.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Li, Q., Chen, Z., Yan, X., He, J., Dong, B., Deng, X., Yan, J., Cheng, S., & Zhang, X. (2026). Engineered Bacterial Protoplasts for Spatiotemporally Controlled Tumor Immunotherapy. Advanced Functional Materials, 36(54). https://doi.org/10.1002/adfm.76486

Vancouver

Zhang Y, Li Q, Chen Z, Yan X, He J, Dong B, et al. Engineered Bacterial Protoplasts for Spatiotemporally Controlled Tumor Immunotherapy. Advanced Functional Materials. 2026;36(54). doi:10.1002/adfm.76486

BibTeX
@article{Zhang2026,
  author = {Zhang, Yun and Li, Qian‐Ru and Chen, Zhu and Yan, Xiao and He, Jin‐Lian and Dong, Bao‐Ting and Deng, Xin‐Chen and Yan, Jian‐Hua and Cheng, Si‐Xue and Zhang, Xian‐Zheng},
  title = {Engineered Bacterial Protoplasts for Spatiotemporally Controlled Tumor Immunotherapy},
  journal = {Advanced Functional Materials},
  year = {2026},
  volume = {36},
  number = {54},
  doi = {10.1002/adfm.76486}
}
Kostenlos starten →